berberine has been researched along with Elevated Cholesterol in 29 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In view of this, we have evaluated the lipid-lowering effect of a nutraceutical pill containing berberine (BBR) and of ezetimibe, as alternative treatments, in monotherapy or in combination, in 228 subjects with primary hypercholesterolemia (HCH), with history of STs intolerance or refusing STs treatment." | 9.16 | Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. ( Bellocchio, A; Bertolini, S; Pisciotta, L, 2012) |
| "In conclusion, this study demonstrates that the combination of monacolin K, berberine and coenzyme Q10 is effective and safe for treating hypercholesterolemia in patients with a moderate degree of excess LDL-C and cardiovascular risk." | 5.51 | Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk. ( Arnás, C; Corbella, E; de Dios, S; Florido, M; Licerán, M; Martin, D; Martinez-Martin, F; Petitbò, D; Pintó, X; Sánchez, A; Sánchez-Hernández, RM; Sarasa, I; Trias, F, 2022) |
| "A double-blind, randomized, placebo-controlled, dose ranging study was carried out that compared three doses of berberine ursodeoxycholate (BUDCA) to placebo in a cohort of subjects with a history of hypercholesterolemia and serum LDL cholesterol levels above 2." | 5.34 | Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. ( Bai, R; Di Bisceglie, AM; Lavin, P; Liu, L; Watts, GF; Yu, M, 2020) |
| " In view of this, we have evaluated the lipid-lowering effect of a nutraceutical pill containing berberine (BBR) and of ezetimibe, as alternative treatments, in monotherapy or in combination, in 228 subjects with primary hypercholesterolemia (HCH), with history of STs intolerance or refusing STs treatment." | 5.16 | Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. ( Bellocchio, A; Bertolini, S; Pisciotta, L, 2012) |
| " We evaluated the effects of a nutraceutical combination (NC), consisting of 500 mg berberine, 200mg red yeast rice and 10mg policosanols, on cholesterol levels and endothelial function in patients with hypercholesterolemia." | 5.14 | Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. ( Affuso, F; Fazio, S; Micillo, F; Ruvolo, A; Saccà, L, 2010) |
| " These results could explain the variability observed in the response to berberine among people with moderate hypercholesterolemia, and they may be useful in identifying patients who could potentially benefit from supplementation with AP." | 3.83 | Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. ( Brea, A; De Castro-Orós, I; Mozas, P; Pocoví, M; Puzo, J; Solà, R; Valls, RM, 2016) |
| "Berberine (BBR) is an isoquinoline plant alkaloid endowed with several pharmacological activities, including anti-microbial, glucose- and cholesterol-lowering, anti-tumoral and immunomodulatory properties." | 2.52 | Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. ( Catapano, AL; Pirillo, A, 2015) |
| "Berberine (BBR) is an effective cholesterol-lowering drug." | 1.72 | The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression. ( Wang, QC; Wu, C; Xu, W; Yang, YN; Yu, J; Zhang, H, 2022) |
| " The safety results indicated that coptisine was a safe and low-toxic compound." | 1.42 | The safety and anti-hypercholesterolemic effect of coptisine in Syrian golden hamsters. ( Chen, B; Fang, X; He, K; Hu, Y; Li, X; Ning, N; Wang, Y; Wu, H; Ye, X; Zou, Z, 2015) |
| " Cholesterol absorption rate was measured with the dual stable isotope ratio method, and plasma lipids were determined using the enzymatic methods." | 1.40 | Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. ( Ghanam, K; Wang, Y; Yi, X; Zhang, S; Zhao, T; Zhu, X, 2014) |
| "Berberine treatment reduced the plasma sugar and lipid levels by 24-69% in the rat model of hyperglycemia and hypercholesterolemia." | 1.37 | Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats. ( Dong, SF; Hao, YZ; Hong, Y; Liu, M; Liu, Y; Sun, JN; Yu, HS, 2011) |
| "Berberine (BBR, 1) is a novel cholesterol-lowering agent that up-regulates low-density-lipoprotein receptor (LDLR) expression through a mechanism different from that of statins." | 1.35 | Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators. ( Cao, RQ; Gao, LM; Jiang, JD; Kong, WJ; Li, YH; Liu, SY; Song, DQ; Wang, YX; Yang, P, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (24.14) | 29.6817 |
| 2010's | 16 (55.17) | 24.3611 |
| 2020's | 6 (20.69) | 2.80 |
| Authors | Studies |
|---|---|
| Martinez-Martin, F | 1 |
| Corbella, E | 1 |
| Sarasa, I | 1 |
| Trias, F | 1 |
| Petitbò, D | 1 |
| Licerán, M | 1 |
| Sánchez-Hernández, RM | 1 |
| Martin, D | 1 |
| Sánchez, A | 1 |
| Arnás, C | 1 |
| de Dios, S | 1 |
| Florido, M | 1 |
| Pintó, X | 1 |
| Yang, YN | 1 |
| Wang, QC | 1 |
| Xu, W | 1 |
| Yu, J | 2 |
| Zhang, H | 1 |
| Wu, C | 1 |
| Fernández-Fernández, FJ | 1 |
| Sardina-Ferreiro, R | 1 |
| Ameneiros-Lago, E | 1 |
| Formisano, E | 1 |
| Pasta, A | 1 |
| Cremonini, AL | 1 |
| Favari, E | 2 |
| Ronca, A | 1 |
| Carbone, F | 1 |
| Semino, T | 1 |
| Di Pierro, F | 1 |
| Sukkar, SG | 1 |
| Pisciotta, L | 2 |
| Di Bisceglie, AM | 1 |
| Watts, GF | 1 |
| Lavin, P | 1 |
| Yu, M | 1 |
| Bai, R | 1 |
| Liu, L | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Cybulska, B | 1 |
| Stoś, K | 1 |
| Tyszko, P | 1 |
| Yu, CY | 1 |
| Liu, GY | 1 |
| Liu, XH | 1 |
| Gui, YZ | 1 |
| Liu, HM | 1 |
| Zheng, HC | 1 |
| Gorecki, DC | 1 |
| Patel, AV | 1 |
| Yu, C | 1 |
| Wang, YP | 1 |
| Zhu, X | 2 |
| Yang, J | 1 |
| Zhu, W | 1 |
| Yin, X | 1 |
| Yang, B | 1 |
| Wei, Y | 1 |
| Guo, X | 1 |
| Li, C | 2 |
| Hu, Z | 1 |
| Zhang, W | 1 |
| Yang, Y | 1 |
| Xu, Z | 1 |
| Luo, H | 1 |
| Liu, X | 1 |
| Liu, Y | 3 |
| Chen, C | 1 |
| Cai, Y | 1 |
| Xia, X | 1 |
| Zhang, X | 1 |
| Wang, DZ | 1 |
| Wu, G | 1 |
| Zeng, C | 1 |
| Hsieh, YL | 1 |
| Yeh, YH | 1 |
| Lee, YT | 1 |
| Hsieh, CH | 1 |
| Cicero, AF | 1 |
| Reggi, A | 1 |
| Parini, A | 1 |
| Morbini, M | 1 |
| Rosticci, M | 1 |
| Grandi, E | 1 |
| Borghi, C | 1 |
| Wang, Y | 4 |
| Yi, X | 1 |
| Ghanam, K | 1 |
| Zhang, S | 1 |
| Zhao, T | 1 |
| Zimetti, F | 1 |
| Adorni, MP | 1 |
| Ronda, N | 1 |
| Gatti, R | 1 |
| Bernini, F | 1 |
| He, K | 1 |
| Ye, X | 1 |
| Wu, H | 2 |
| Zou, Z | 1 |
| Ning, N | 1 |
| Hu, Y | 1 |
| Chen, B | 1 |
| Fang, X | 1 |
| Li, X | 1 |
| Mazza, A | 1 |
| Lenti, S | 1 |
| Schiavon, L | 1 |
| Zuin, M | 1 |
| D'Avino, M | 1 |
| Ramazzina, E | 1 |
| Casiglia, E | 1 |
| Pirillo, A | 1 |
| Catapano, AL | 1 |
| De Castro-Orós, I | 1 |
| Solà, R | 1 |
| Valls, RM | 1 |
| Brea, A | 1 |
| Mozas, P | 1 |
| Puzo, J | 1 |
| Pocoví, M | 1 |
| Kong, WJ | 3 |
| Wei, J | 2 |
| Zuo, ZY | 2 |
| Wang, YM | 2 |
| Song, DQ | 3 |
| You, XF | 1 |
| Zhao, LX | 1 |
| Pan, HN | 1 |
| Jiang, JD | 5 |
| Yang, P | 2 |
| Li, YH | 2 |
| Wang, YX | 2 |
| Gao, LM | 2 |
| Liu, SY | 1 |
| Cao, RQ | 1 |
| Hu, CQ | 1 |
| Gao, H | 1 |
| Feng, YC | 1 |
| Du, NN | 1 |
| Affuso, F | 1 |
| Ruvolo, A | 1 |
| Micillo, F | 1 |
| Saccà, L | 1 |
| Fazio, S | 1 |
| Dong, SF | 1 |
| Hong, Y | 1 |
| Liu, M | 1 |
| Hao, YZ | 1 |
| Yu, HS | 1 |
| Sun, JN | 1 |
| Marazzi, G | 1 |
| Cacciotti, L | 1 |
| Pelliccia, F | 1 |
| Iaia, L | 1 |
| Volterrani, M | 1 |
| Caminiti, G | 1 |
| Sposato, B | 1 |
| Massaro, R | 1 |
| Grieco, F | 1 |
| Rosano, G | 1 |
| Liu, F | 1 |
| Gan, PP | 1 |
| Woo, WS | 1 |
| Ong, ES | 1 |
| Li, SF | 1 |
| Bellocchio, A | 1 |
| Bertolini, S | 1 |
| Kong, W | 1 |
| Abidi, P | 2 |
| Lin, M | 1 |
| Inaba, S | 1 |
| Wang, Z | 1 |
| Si, S | 1 |
| Pan, H | 1 |
| Wang, S | 1 |
| Wu, J | 1 |
| Li, Z | 1 |
| Liu, J | 2 |
| Doggrell, SA | 1 |
| Zhou, Y | 1 |
| Iijima, OT | 1 |
| Takeda, H | 1 |
| Matsumiya, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia[NCT03381287] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2018-04-13 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| To Test the Efficacy of Novel Berberine Emulsification by TPGS or Quillaja Extract on the Absorption of Berberine Compared to Berberine Powder in Humans[NCT03438292] | 32 participants (Actual) | Interventional | 2018-09-25 | Completed | |||
| A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders[NCT02983188] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2018-04-25 | Completed | ||
| The Effect of Policosanol on Elderly Patients With Endothelial Dysfunction[NCT02543099] | Phase 3 | 100 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Effect of a Nutraceutical Combination on Endothelial Injury and C-reactive Protein in Patients With Low-grade Systemic Inflammation[NCT02422927] | Phase 4 | 100 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| The Study of Berberine Affecting Metabolism, Inflammation Status, Endothelial Function and Thrombotic Events in Patients With Coronary Artery Disease by Remodeling Gut Microbiota[NCT04434365] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2019-06-21 | Active, not recruiting | ||
| Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus[NCT00633282] | Phase 2 | 184 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572] | Phase 4 | 120 participants (Anticipated) | Interventional | 2017-08-16 | Recruiting | ||
| Assess the Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus Among Individuals With High Cardiometabolic Risk[NCT05749874] | Phase 4 | 6,500 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| Efficacy and Safety of Berberine on Primary Prevention of Cardiovascular Diseases and Diabetes in Metabolic Syndrome: a Randomized, Controlled Trial[NCT05105321] | Phase 4 | 5,200 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 28
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg BID | 1.770 | 3370 |
| HTD1801 250 mg BID | 0.676 | 962 |
| HTD1801 500 mg BID | 1.510 | 1900 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg | 0.865 | 2900 |
| HTD1801 250 mg | 0.390 | 923 |
| HTD1801 500 mg | 0.441 | 1900 |
TEAEs are defined as any AEs that commenced on or after exposure to study drug or any pre-existing AE that worsened in either intensity or frequency after exposure to study drug. (NCT03381287)
Timeframe: 4 weeks
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| TEAE | Serious TEAE | Severe TEAE | Drug-related TEAEs | TEAEs leading to treatment interrupted or discontinued | |
| HTD1801 1000 mg BID | 11 | 1 | 0 | 6 | 1 |
| HTD1801 250 mg BID | 10 | 0 | 0 | 2 | 0 |
| HTD1801 500 mg BID | 8 | 0 | 0 | 7 | 0 |
| Placebo | 8 | 0 | 1 | 4 | 0 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -32.192 | -34.382 |
| HTD1801 250 mg BID | -38.672 | -46.458 |
| HTD1801 500 mg BID | -41.295 | 47.246 |
| Placebo | -41.743 | -33.153 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -13.034 | -21.916 |
| HTD1801 250 mg BID | -19.527 | -11.239 |
| HTD1801 500 mg BID | 222.4113 | 242.570 |
| Placebo | -4.975 | 10.582 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -9.296 | -9.767 |
| HTD1801 250 mg BID | -3.390 | -7.674 |
| HTD1801 500 mg BID | -1.1550 | 0.372 |
| Placebo | 3.624 | -3.585 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -2.240 | 6.256 |
| HTD1801 250 mg BID | -5.788 | 7.684 |
| HTD1801 500 mg BID | 12.798 | 25.882 |
| Placebo | 1.724 | 36.778 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 28
| Intervention | hours (Mean) |
|---|---|
| Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg BID | 7.53 |
| HTD1801 500 mg BID | 7.60 |
(NCT03381287)
Timeframe: 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 1
| Intervention | hours (Mean) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg | 7.79 | 5.24 |
| HTD1801 250 mg | 9.04 | 2.79 |
| HTD1801 500 mg | 10.60 | 8.43 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 28
| Intervention | hours (Median) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg BID | 4.0 | 3.0 |
| HTD1801 250 mg BID | 4.0 | 3.0 |
| HTD1801 500 mg BID | 4.0 | 4.0 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 1
| Intervention | hours (Median) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg | 4.0 | 4.0 |
| HTD1801 250 mg | 3.5 | 2.0 |
| HTD1801 500 mg | 4.0 | 3.0 |
2 reviews available for berberine and Elevated Cholesterol
| Article | Year |
|---|---|
Hypolipaemic nutraceutics: red yeast rice and Armolipid, berberine and bergamot.
Topics: Berberine; Biological Products; Cholesterol; Citrus; Clinical Trials as Topic; Dietary Supplements; | 2021 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Topics: Animals; Anticholesteremic Agents; Berberine; Biomarkers; Blood Glucose; Cholesterol; Diabetes Melli | 2015 |
10 trials available for berberine and Elevated Cholesterol
| Article | Year |
|---|---|
Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk.
Topics: Berberine; Cardiovascular Diseases; Cholesterol, LDL; Dietary Supplements; Heart Disease Risk Factor | 2022 |
Efficacy of Nutraceutical Combination of Monacolin K, Berberine, and Silymarin on Lipid Profile and PCSK9 Plasma Level in a Cohort of Hypercholesterolemic Patients.
Topics: Berberine; Dietary Supplements; Humans; Hypercholesterolemia; Lipids; Lovastatin; Proprotein Convert | 2020 |
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.
Topics: Adult; Aged; Berberine; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; D | 2020 |
Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Berberine; Cardiovascular Diseases; Contraception; Contraceptives, | 2014 |
Nutraceuticals for Serum Lipid and Blood Pressure Control in Hypertensive and Hypercholesterolemic Subjects at Low Cardiovascular Risk.
Topics: Berberine; Biological Products; Blood Pressure; Cardiovascular Diseases; Diet; Dietary Supplements; | 2015 |
Combination of simvastatin with berberine improves the lipid-lowering efficacy.
Topics: Animals; Berberine; Cholesterol, LDL; Drug Synergism; Drug Therapy, Combination; Fatty Liver; Humans | 2008 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study.
Topics: Anticholesteremic Agents; Berberine; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Sup | 2010 |
Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Berberine; Biological Products; Blood Glucose; Ch | 2011 |
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment.
Topics: Aged; Anticholesteremic Agents; Azetidines; Berberine; Biological Products; Cholesterol, LDL; Dietar | 2012 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
Topics: Animals; Anticholesteremic Agents; Berberine; Blotting, Northern; China; Cholesterol; Cholesterol, L | 2004 |
17 other studies available for berberine and Elevated Cholesterol
| Article | Year |
|---|---|
The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression.
Topics: Animals; Bacteria; Berberine; Butyrates; Cholesterol; Diet, High-Fat; Hypercholesterolemia; Hyperlip | 2022 |
[Nutraceuticals (monacolin K, berberine and coenzyme Q10) in patients with moderate hypercholesterolemia and low-moderate cardiovascular risk. Potential benefits of combined therapies].
Topics: Berberine; Cardiovascular Diseases; Dietary Supplements; Heart Disease Risk Factors; Humans; Hyperch | 2023 |
Proteomics analysis reveals a potential new target protein for the lipid-lowering effect of Berberine8998.
Topics: Animals; Anticholesteremic Agents; Berberine; Biological Availability; Cholesterol, LDL; Cricetinae; | 2018 |
Combination of Berberine with Resveratrol Improves the Lipid-Lowering Efficacy.
Topics: 3T3-L1 Cells; Administration, Oral; Animals; Berberine; Cholesterol; Cholesterol, LDL; Diet, High-Fa | 2018 |
Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Benzoates; Benzylamines; Berberine; Cholest | 2019 |
Ameliorative effect of Pracparatum mungo extract on high cholesterol diets in hamsters.
Topics: Animals; Antioxidants; Berberine; Cholesterol; Cricetinae; Glycyrrhizic Acid; Humans; Hydroxymethylg | 2014 |
Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption.
Topics: Animals; Anticholesteremic Agents; Berberine; Caco-2 Cells; Cell Membrane Permeability; Cholesterol; | 2014 |
The natural compound berberine positively affects macrophage functions involved in atherogenesis.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Berberine; Cell Membrane; Cells, Cultured; Chemo | 2015 |
The safety and anti-hypercholesterolemic effect of coptisine in Syrian golden hamsters.
Topics: Animals; Anticholesteremic Agents; Berberine; Cholesterol; Cricetinae; Diet, High-Fat; Down-Regulati | 2015 |
Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine.
Topics: Adult; Aged; Alleles; Berberine; Cholesterol, LDL; Fatty Alcohols; Female; Heterozygote; Humans; Hyp | 2016 |
Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators.
Topics: Benzene; Berberine; Chemistry, Pharmaceutical; Drug Design; Humans; Hypercholesterolemia; Ions; Lipi | 2008 |
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
Topics: Animals; Berberine; Cholesterol; Hepatocytes; Humans; Hypercholesterolemia; Magnetic Resonance Spect | 2009 |
Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats.
Topics: Animals; Berberine; Biomarkers; Dietary Fats; Gene Expression Regulation; Glucose Transporter Type 4 | 2011 |
A combination of metabolomics and metallomics studies of urine and serum from hypercholesterolaemic rats after berberine injection.
Topics: Animals; Berberine; Coptis; Hypercholesterolemia; Magnetic Resonance Spectroscopy; Mass Spectrometry | 2012 |
Berberine--a novel approach to cholesterol lowering.
Topics: Animals; Anticholesteremic Agents; Berberine; Clinical Trials as Topic; Cricetinae; Drugs, Investiga | 2005 |
Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine.
Topics: 3' Untranslated Regions; Berberine; Bile Acids and Salts; Carcinogens; Carcinoma, Hepatocellular; Ce | 2005 |
Effects of San'o-shashin-to on the antioxidative mechanism in spontaneous familial hypercholesterolaemic rabbits.
Topics: Animals; Antioxidants; Berberine; Drugs, Chinese Herbal; Erythrocyte Membrane; Hypercholesterolemia; | 2000 |